BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 28946761)

  • 1. Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I Disorder.
    Szegedi A; Durgam S; Mackle M; Yu SY; Wu X; Mathews M; Landbloom RP
    Am J Psychiatry; 2018 Jan; 175(1):71-79. PubMed ID: 28946761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar I Disorder.
    Findling RL; Landbloom RL; Szegedi A; Koppenhaver J; Braat S; Zhu Q; Mackle M; Chang K; Mathews M
    J Am Acad Child Adolesc Psychiatry; 2015 Dec; 54(12):1032-41. PubMed ID: 26598478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asenapine: Efficacy and safety of 5 and 10mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder.
    Landbloom RL; Mackle M; Wu X; Kelly L; Snow-Adami L; McIntyre RS; Mathews M; Hundt C
    J Affect Disord; 2016 Jan; 190():103-110. PubMed ID: 26496015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension.
    Szegedi A; Calabrese JR; Stet L; Mackle M; Zhao J; Panagides J;
    J Clin Psychopharmacol; 2012 Feb; 32(1):46-55. PubMed ID: 22198448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia.
    Findling RL; Landbloom RP; Mackle M; Pallozzi W; Braat S; Hundt C; Wamboldt MZ; Mathews M
    J Child Adolesc Psychopharmacol; 2015 Jun; 25(5):384-96. PubMed ID: 26091193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and tolerability of asenapine: A double-blind, uncontrolled, long-term extension trial in adults with an acute manic or mixed episode associated with bipolar I disorder.
    Ketter TA; Durgam S; Landbloom R; Mackle M; Wu X; Mathews M
    J Affect Disord; 2017 Jan; 207():384-392. PubMed ID: 27755982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose Trial.
    Findling RL; Landbloom RL; Mackle M; Wu X; Snow-Adami L; Chang K; Durgam S
    Paediatr Drugs; 2016 Oct; 18(5):367-78. PubMed ID: 27461426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study.
    McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
    J Affect Disord; 2010 Nov; 126(3):358-65. PubMed ID: 20537396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
    McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
    J Affect Disord; 2010 Apr; 122(1-2):27-38. PubMed ID: 20096936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder.
    Vieta E; Montgomery S; Sulaiman AH; Cordoba R; Huberlant B; Martinez L; Schreiner A
    Eur Neuropsychopharmacol; 2012 Nov; 22(11):825-35. PubMed ID: 22503488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses.
    Azorin JM; Sapin C; Weiller E
    J Affect Disord; 2013 Feb; 145(1):62-9. PubMed ID: 22868059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment.
    Kane JM; Mackle M; Snow-Adami L; Zhao J; Szegedi A; Panagides J
    J Clin Psychiatry; 2011 Mar; 72(3):349-55. PubMed ID: 21367356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states.
    McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
    Bipolar Disord; 2009 Nov; 11(7):673-86. PubMed ID: 19839993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder.
    Keck PE; Calabrese JR; McQuade RD; Carson WH; Carlson BX; Rollin LM; Marcus RN; Sanchez R;
    J Clin Psychiatry; 2006 Apr; 67(4):626-37. PubMed ID: 16669728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asenapine: a review of its use in the management of mania in adults with bipolar I disorder.
    Chwieduk CM; Scott LJ
    CNS Drugs; 2011 Mar; 25(3):251-67. PubMed ID: 21323396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study.
    Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry P; Hertel P; Such P; Salzman PM; McQuade RD; Nyilas M; Carson WH
    J Clin Psychiatry; 2017 Mar; 78(3):324-331. PubMed ID: 28146613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asenapine treatment and health-related quality of life in patients experiencing bipolar I disorder with mixed episodes: post-hoc analyses of pivotal trials.
    Michalak EE; Guiraud-Diawara A; Sapin C
    Curr Med Res Opin; 2014 Apr; 30(4):711-8. PubMed ID: 24329543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.
    Bowden CL; Vieta E; Ice KS; Schwartz JH; Wang PP; Versavel M
    J Clin Psychiatry; 2010 Feb; 71(2):130-7. PubMed ID: 20122373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.